Modular phase 2 study to link combination immune-therapy to patients with advanced solid and hematologic malignancies Module 9: PDR001 plus LAG525 for patients with advanced solid and hematologic malignancies

Principal Investigator

Jacqueline Vuky

Study Purpose

The purpose of this study is to evaluate how safe and effective the combination of PDR001 and LAG525 is for patients with various types of cancer.

Medical Condition(s)

Small cell lung cancer
Gastric/esophageal adenocarcinoma
Castration resistant prostate adenocarcinoma (CRPC)
Soft tissue sarcoma
Ovarian adenocarcinoma
Advanced well-differentiated neuroendocrine tumors*
Diffuse large B cell lymphoma (DLBCL)

Eligibility Criteria

1. Men and women 18 years or older
2. Locally advanced solid tumors and hematologic malignancies
3. Adequate organ function
4. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed


Duration of Participation

You will receive the study drug for as long as you and the investigator feel that you are tolerating the study drug and the investigator feels it is in your best interest to continue receiving study drug; you follow directions of the investigator; or if you are female and able to become pregnant, you do not become pregnant. After you finish treatment, you will have safety follow-up visits to see how you are feeling 30, 90, and 150 days from your last dose of study drug. if you are a women with childbearing potential, you will also require urine pregnancy test to be performed on 30, 60, 90, 120, and 150 days from your last dose of study drug.

Minors Included



Knight Clinical Trials Information Line


Novartis Pharmaceuticals

Recruitment End


Compensation Provided


Go Back